Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03711578
Recruitment Status : Completed
First Posted : October 18, 2018
Last Update Posted : October 19, 2020
Sponsor:
Information provided by (Responsible Party):
Rhizen Pharmaceuticals SA

Brief Summary:
To assess the anti-tumor activity and safety of Tenalisib in patients with relapsed/refractory indolent Non-Hodgkin's Lymphoma (iNHL),

Condition or disease Intervention/treatment Phase
Non Hodgkin Lymphoma Drug: Tenalisib, Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Phase II Study to Evaluate the Efficacy and Safety of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Adult Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)
Actual Study Start Date : November 25, 2018
Actual Primary Completion Date : June 16, 2020
Actual Study Completion Date : October 16, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: Tenalisib
Participants receive Tenalisib 800 mg BID in 28-Days Cycle for 8 Cycles
Drug: Tenalisib,
BID, Orally
Other Name: RP6530




Primary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: 7 months ]
    ORR is defined as sum of CR and PR rates and will be assessed according to the Lugano Classification for initial evaluation, staging, and response assessment of Non-Hodgkin lymphoma. (Cheson-2014)

  2. Complete response rate [ Time Frame: 7 months ]
    CR rate will be assessed according to the Lugano Classification for initial evaluation, staging, and response assessment of non-Hodgkin lymphoma.

  3. Progression Free Survival (PFS) [ Time Frame: 7 months ]
    PFS is defined as the time of the first dose of Tenalisib to disease progression or death.

  4. Duration of Response (DoR) [ Time Frame: 7 months ]
    DoR is measured from the initial response to disease progression or death


Secondary Outcome Measures :
  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 7 months ]
    Safety and tolerability of Tenalisib



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with histologically confirmed diagnosis of indolent B-cell NHL, with histological subtype limited to:

    1. Follicular lymphoma (FL) G1, G2, or G3a
    2. Marginal zone lymphoma (MZL) (splenic, nodal, or extra-nodal)
    3. Lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL/WM)
    4. Small lymphocytic lymphoma (SLL) with absolute lymphocyte count <5 x10^9/L at the time of diagnosis and at study entry.
  2. Relapsed or refractory after ≥ 2 prior lines of therapy (refractory defined as not responding to a standard regimen or progressing within 6 months of the last course of a standard regimen). Patients must have received rituximab and alkylating agents.
  3. Patients must have at least one bi-dimensionally measurable lesion (that has not been previously irradiated) with the longest diameter ≥ 1.5 cm.
  4. Male or female patients > 18 years of age.
  5. ECOG performance status ≤ 2.
  6. Life expectancy of at least 3 months.
  7. Adequate bone marrow, liver, and renal function as assessed by the following laboratory requirements conducted within 7 days before starting study treatment:

    1. Hemoglobin ≥ 9 g/dl
    2. Absolute neutrophil count (ANC) ≥ 1 x 10^9/L
    3. Platelets ≥50 x 10^9/L (patient without BM involvement) and 30 x 10^9/L (patient with BM involvement)
    4. Total bilirubin ≤1.5 times the upper limit of normal (ULN)
    5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 x ULN if known liver involvement
    6. Creatinine ≤ 1.5 mg/dL OR calculated creatinine clearance ≥ 50 mL/min (as calculated by the Cockcroft-Gault method)
  8. Use of an effective means of contraception for female patients of child-bearing potential, and all male partners.
  9. Willingness and ability to comply with trial and follow-up procedures, give written informed consent.

Exclusion Criteria:

  1. FL grade 3b or transformed disease or CLL
  2. Cancer therapy within 3 weeks (21 days) or 5 half-lives (whichever is shorter) prior to C1D1. Corticosteroids (prednisone or equivalent) at a dose of < 20 mg daily are allowed. Corticosteroid should be stabilized for at least 1 week prior to C1D1
  3. Auto-SCT within 3 months from C1D1 (patients must not have active graft versus- host disease)
  4. History of having received an Allo-SCT
  5. Active hepatitis B or C infection
  6. Known history of human immunodeficiency virus (HIV) infection
  7. Evidence of ongoing severe systemic bacterial, fungal or viral infection
  8. Known primary central nervous system lymphoma or any preexisting neurologic manifestations
  9. Known history of drug-induced liver injury, alcoholic liver disease, primary biliary cirrhosis, ongoing extrahepatic obstruction caused by stones, cirrhosis of the liver or portal hypertension;
  10. Prior exposure to drug that specifically inhibits PI3K
  11. Pregnancy or lactation
  12. Myeloid growth factors or red blood cells/ platelet transfusion within 14 days prior to C1D1
  13. Drug administration within 1 week prior to C1D1

    1. Strong inhibitors or inducers of CYP3A4, CYP2C9, including grapefruit products, herbal supplements and drugs
    2. Substrates of CYP3A4 enzyme with a narrow therapeutic range

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03711578


Locations
Layout table for location information
United States, Alabama
Clearview Cancer Institute
Huntsville, Alabama, United States, 35805
United States, Colorado
Colorado Blood Cancer Institute
Denver, Colorado, United States, 80218
United States, Florida
Florida cancer specialists & Research Institute
Florida City, Florida, United States, 33401
Florida Cancer Specialist/ South
Fort Myers, Florida, United States, 33908
Florida Cancer Specialists/North
Saint Petersburg, Florida, United States, 33705
United States, Missouri
HCA Midwest Health Kansas City
Kansas City, Missouri, United States, 64132
United States, Tennessee
Tennessee Oncology
Chattanooga, Tennessee, United States, 37404
Tennessee Oncology
Nashville, Tennessee, United States, 37203
Australia, New South Wales
Blacktown Hospital, Blacktown Cancer and Haematology Center
Blacktown, New South Wales, Australia, 2148
Australia, Queensland
Brisbane Clinic for Lymphoma, Myeloma and Leukaemia,
Greenslopes,, Queensland, Australia, 4120
John Flynn Private Hospital,
Tugun, Queensland, Australia, 4224
Australia, South Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia, 5000
Sponsors and Collaborators
Rhizen Pharmaceuticals SA
Layout table for additonal information
Responsible Party: Rhizen Pharmaceuticals SA
ClinicalTrials.gov Identifier: NCT03711578    
Other Study ID Numbers: RP6530-1802
First Posted: October 18, 2018    Key Record Dates
Last Update Posted: October 19, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Rhizen Pharmaceuticals SA:
Non-Hodgkin lymphoma,
Tenalisib
RP6530
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases